Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report
Brand Name Pharmaceutical Manufacturing in the US
Over the five years to 2019, the Brand Name Pharmaceutical Manufacturing industry in the United States experienced several new drug launches, with 54 new active substances launched in 2017 alone. Given increasing price scrutiny, competition from generics and rising research and development expenses, many manufacturers shifted their strategic focus to more lucrative therapy areas, such as rare diseases and oncology. Furthermore, generics account for the majority of prescription drugs in the United States and are expected to capture a growing size of the market following approaching patent expirations of numerous top-selling drugs. In addition, many brand name manufacturers expanded their product portfolios to include biologic drugs. Overall, industry revenue is anticipated to increase during the current period. Over the five years to 2024, industry revenue is forecast to continue to rise. Many industry operators are expected to drive sales volumes from biologic drugs, while also raising prices on widely used specialty drugs.
Pharmaceutical manufacturers develop prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Brand-name drugs and medication have patent protection. This industry does not include nutritional supplement or cosmetic product manufacturers.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook